SCHEMBL4576513

SCHEMBL4576513

N=C1NCCN1c1c(Cl)cccc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 2/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
HTR2C P28335 3/20 0.33
HTR2B P41595 2/20 0.33
ITGB3 P05106 1/20 0.33
ITGB1 P05556 1/20 0.33
ITGAV P06756 1/20 0.33
ITGA5 P08648 1/20 0.33
ITGA4 P13612 1/20 0.33
ITGB5 P18084 1/20 0.33
ITGB8 P26012 1/20 0.33
HTR2A P28223 2/20 0.33
NOTUM Q6P988 2/20 0.33
ALDH1A1 P00352 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MAPT P10636 2/20 0.32
ALOX5 P09917 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28715258 0.78 GAA (0.41) ADRB1HTR2CHTR2BALDH1A1MAPT
SCHEMBL6407806 0.75 P2RX7 (0.31)
SCHEMBL6407367 0.74
SCHEMBL6407183 0.74
SCHEMBL24709283 0.71 SIGMAR1 (0.54) ADRB1TDP1MAPTALOX5
Bromide SCHEMBL31141400 0.69 SIGMAR1 (0.52) ADRB1TDP1MAPTALOX5
SCHEMBL6408708 0.68
SCHEMBL19357378 0.68 SLC6A4 (0.48) ADRB1DRD2DRD3HTR2CHTR2B
SCHEMBL10800951 0.67 KEAP1 (0.44) ADRB1ALDH1A1MAPTSMN1; SMN2
SCHEMBL2581074 0.67 CYP1A2 (0.40) NOTUMALDH1A1MAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653259-B2 Process for synthesizing heterocyclic compounds SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2014-02-18 US disclosed
US-20080146797-A1 PROCESS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-06-19 US disclosed
US-20040242560-A1 Process for synthesizing heterocyclic compounds AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146797-A1 PROCESS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS TST, NISCH, CLIC4 ADRB1 3908/4885DRD2 2841/4885DRD3 3797/4885
US-20040242560-A1 Process for synthesizing heterocyclic compounds TST, NISCH, CLIC4 ADRB1 3950/4885DRD2 2854/4885DRD3 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.